Market research
04IC.F InVivo Therapeutics Holdings Corp
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.07
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.07
About
About InVivo Therapeutics Holdings Corp
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 04IC.F discussion.
5 years, 4 months ago
InVivo Therapeutics Holdings Corp is currently in a long term downtrend where the price is trading 26.5% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
InVivo Therapeutics Holdings Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 35.0% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 2.4% to $-2M since the same quarter in the previous year.
Based on the above factors, InVivo Therapeutics Holdings Corp gets an overall score of 2/5.